[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
D000616:Aminoglutethimide / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003348:Cortisone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009362:Neoplasm Metastasis; D011897:Random Allocation
D000970:Antineoplastic Agents; D000616:Aminoglutethimide; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D003348:Cortisone
Aminoglutethimid plus hochdosiertes Medroxyprogesteronazetat versus Aminoglutethimid plus Kortison in der Therapie des metastasierenden Mammakarzinoms. Eine AIO1-Phase-III-Studie.